Dashboard
Financial statements
ABBV

Company financials

AbbVie

Health Care Biotechnology North Chicago, Illinois Last filing Feb 20, 2026 · FY2025
Revenue FY2025
$61.2B
3y CAGR +1.8% P29
Net income FY2025
$4.2B
Net margin +6.9% P25
Total assets FY2025
$134.0B
ROA +3.2% P25
Operating cash flow FY2025
$19.0B
FCF margin +29.1% P96
15 yrs · FY2011–FY2025 8 filed · 1 derived · 0 blank

Year-over-year change per cell; first column has no prior.

Balance Sheet

Assets, liabilities, and equity

26 accounts · 10 years
Total assets $134.0B
Total liabilities ~$137.2B
Shareholders equity $-3.3B
Account 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 Trend
Assets
Cash and Cash Equivalents -5.3% -56.9% +39.3% -5.6% +15.4% -78.8% +447.7% -21.6% +82.4% —
Short Term Investments -9.7% +1450.0% -92.9% -66.7% +180.0% — -100.0% +58.8% -63.3% —
Accounts Receivable +15.3% -2.1% -0.9% +12.8% +13.1% +62.5% +0.8% +5.8% +6.9% —
Inventory +18.4% +2.0% +14.5% +14.4% -5.5% +82.6% +13.0% +0.0% +11.1% —
Prepaid Expenses +27.2% -0.1% +12.1% -11.9% +40.2% +51.3% +24.2% -60.0% +33.1% —
Total Current Assets +13.6% -22.5% +15.9% +1.9% +15.5% -51.2% +192.2% -20.2% +31.1% —
Property,Plant and Equipment +9.6% +2.9% +1.1% -3.4% -2.6% +77.2% +2.7% +2.9% +7.6% —
Goodwill +2.0% +8.2% +0.4% -0.7% -2.2% +112.3% -0.4% -0.8% +2.4% —
Intangible Assets -12.4% +8.0% -17.5% -11.2% -8.4% +344.4% -12.2% -23.0% -4.6% —
Long Term Investments -3.9% -8.2% +26.1% -13.0% -5.5% +215.1% -93.5% -32.1% +17.2% —
Other Noncurrent Assets +17.3% +7.4% +52.8% +14.1% +0.7% +112.0% +89.4% -8.9% +9.4% —
Total Assets -0.9% +0.3% -2.9% -5.3% -2.7% +69.0% +50.1% -16.2% +7.1% —
Liabilities
Accounts Payable +8.7% +4.2% +20.7% +11.9% +12.6% +70.4% -0.8% +16.7% +9.0% —
Current Portion of Long Term Debt +25.7% -5.4% +73.9% -66.9% +47.0% +126.5% -29.3% -17.3% +1495.8% —
Total Current Liabilities +11.7% +2.4% +28.1% -16.1% +22.8% +83.9% -9.6% +3.6% +70.1% —
Long Term Debt -2.3% +15.6% -11.7% -7.9% -17.2% +23.2% +79.9% +13.1% -15.1% —
Deferred Tax Liabilities -7.4% +32.1% -10.9% -27.2% -17.5% +222.7% +5.9% -57.1% -63.9% —
Other Noncurrent Liabilities +8.1% -6.8% +5.5% +6.8% +4.0% +56.9% +21.4% -7.1% +86.8% —
Equity
Common Stock +0.0% +0.0% +0.0% +0.0% +0.0% +0.0% +0.0% +0.0% +0.0% —
Additional Paid In Capital +5.4% +5.7% +4.9% +5.1% +5.3% +14.4% +3.0% +3.4% +4.3% —
Retained Earnings -96.1% -690.0% -120.9% +53.0% +196.4% -77.6% +40.1% -38.3% +24.7% —
Treasury Stock +11.5% +25.5% +42.2% +46.2% +38.8% -90.8% +1.6% +102.2% +9.9% —
Accumulated Other Comprehensive Income +40.6% +16.5% -4.8% +24.1% +7.0% +13.3% -45.0% +9.1% -5.5% —
Total Stockholders Equity -198.3% -67.9% -40.0% +12.0% +17.8% +260.0% +3.2% -265.7% +9.9% —
Noncontrolling Interest +7.7% +5.4% +12.1% +17.9% +33.3% — — — — —
Total Liabilitiesand Equity -0.9% +0.3% -2.9% -5.3% -2.7% +69.0% +50.1% -16.2% +7.1% —

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 10 years
Ratio 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Profitability
Gross margin +70.2% +70.0% +62.4% +70.0% +69.0% +66.4% +77.6% +76.4% +75.0% +77.3%
Operating margin +24.6% +16.2% +23.5% +31.2% +31.9% +24.8% +39.0% +19.5% +33.8% +36.4%
Net margin +6.9% +7.6% +9.0% +20.4% +20.5% +10.1% +23.7% +17.4% +18.8% +23.2%
FCF margin +29.1% +31.7% +40.6% +41.8% +39.1% +36.7% +38.4% +39.0% +33.4% +25.6%
Growth
Revenue CAGR (3y) +1.8% +0.1% +5.8% +20.4% +19.7% +17.5% +9.1% +12.7% +12.2% +10.9%
Returns
ROE -129.2% +128.7% +46.9% +68.6% +74.9% +35.3% -96.5% -67.3% +104.2% +128.4%
ROA +3.2% +3.2% +3.6% +8.5% +7.9% +3.1% +8.8% +9.6% +7.5% +9.0%
ROIC +16.4% +14.1% +17.5% +22.3% +19.4% +12.5% +65.2% +26.0% +19.8% +19.4%
Liquidity
Current ratio 0.67x 0.66x 0.87x 0.96x 0.79x 0.84x 3.18x 0.98x 1.28x 1.65x
Quick ratio 0.41x 0.42x 0.63x 0.69x 0.56x 0.60x 2.91x 0.74x 0.86x 1.01x
Leverage
D/E -41.97x 39.65x 12.00x 7.04x 8.51x 10.51x -11.90x -8.03x 12.89x 13.26x
Interest coverage 5.74x 4.23x 7.58x — — 4.98x — — 9.51x 9.68x
Efficiency
Asset turnover 0.46x 0.42x 0.40x 0.42x 0.38x 0.30x 0.37x 0.55x 0.40x 0.39x
Cash conversion cycle -522d -529d -400d -387d -345d -329d -432d -428d -381d -429d

Valuation

Price against fundamentals

ABBV $218 · 2025-09-12 · 414d old · FY2025
Market cap $387.1B
P/E 91.60x
P/S 6.33x
P/B —
EV $449.4B
EV/EBITDA —
FCF yield +4.6%
Dividend yield +3.0%

Notes

Your annotations

Not watched
Saving notes adds ABBV to your watchlist.